Endocrine Abstracts

Aim: One of the hallmarks of type 2 diabetes (T2D) is impaired beta cell function, which develops in part as a result of widespread cellular de-differentiation. The current state-of-the-art defines beta cells as a heterogeneous islet population, with the existence of individual subpopulations including specialised ‘pacemakers’. We sought here to understand how overexpression-induced beta cell maturity affects such heterogeneity, befo...

Aim: One of the hallmarks of type 2 diabetes (T2D) is impaired beta cell function, which develops in part as a result of widespread cellular de-differentiation. The current state-of-the-art defines beta cells as a heterogeneous islet population, with the existence of individual subpopulations including specialised ‘pacemakers’. We sought here to understand how overexpression-induced beta cell maturity affects such heterogeneity, befo...

Background: A normal islet includes both mature and immature β-cells, with the former possessing higher insulin content and the latter displaying better proliferative capacity. However, it remains unknown whether immature β-cells also contribute to the regulation of insulin release, especially by commanding the activity of their mature counterparts.Materials and methods: Pdx1, Mafa, and Ngn3 were overexpressed in &#94...

Aim: Vitamin D-binding protein (DBP), also known as GC-globulin, transports vitamin D metabolites and is also a major actin scavenger. While DBP serum levels, gene polymorphisms and autoantigens have been associated with diabetes risk, the underlying mechanisms remain unknown. DBP is produced by the liver, but has recently been shown to be highly expressed in pancreatic α-cells. We therefore sought to investigate the role of DBP in α-cell identity and function using ...

The ability of the thyroid to accumulate iodide via the sodium-iodide symporter (NIS) can be utilised to successfully treat the majority of thyroid cancers with radioiodide. However, approximately 25% of thyroid cancers lose this functional NIS activity and become unresponsive to radioiodide therapy, resulting in a poorer prognosis. Our knowledge of NIS regulation is limited, but as dimerisation of NIS has been proposed, we sought to investigate NIS dimerisation and its impact...

The ability of the thyroid to accumulate iodide via the sodium-iodide symporter (NIS) can be utilised to successfully treat the majority of thyroid cancers with radioiodide. However, approximately 25% of thyroid cancers lose this functional NIS activity and become unresponsive to radioiodide therapy, resulting in a poorer prognosis. Our knowledge of NIS regulation is limited, but as dimerisation of NIS has been proposed, we sought to investigate NIS dimerisation and its impact...